Registration is now closed,
as this program has already taken place.

Tuesday, April 21, 2015

Continuing Education Dinner Activity
6:00 PM - 8:30 PM

Sonesta Hotel Philadelphia
Wyeth Gallery C, 2nd Floor
1800 Market Street
Philadelphia, PA 19103

PROGRAM AGENDA
6:00 PM Registration and Dinner
6:45 PM Welcome
Lauren Berger, MPH, LLS
Ilana Benyosef, LSW, LLS
Edward A. Stadtmauer, MD
7:00 PM Case 1: Who is the appropriate candidate with multiple myeloma (MM) for autologous stem cell transplant (ASCT)?
  R. Bradley Slease, MD
7:30 PM Case 2: What is the current approach to ASCT and consolidation/maintenance for the standard risk MM patient?
  Henry C. Fung, MD, FACP, FRCPE
8:00 PM Case 3: What is the best approach to SCT and consolidation for the "high risk" MM patient including the role of allogeneic SCT?
  Manish Sharma, MD
8:30 PM Adjourn

FACULTY

Edward A. Stadtmauer, MD, Moderator
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

R. Bradley Slease, MD
Christiana Care Health System
Newark, Delaware

Henry C. Fung, MD, FACP, FRCPE
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Manish Sharma, MD
Kimmel Cancer Center
Thomas Jefferson University
Philadelphia, Pennsylvania

MYELOMA ROUNDS ADVISORY GROUP

Edward A. Stadtmauer, MD, Chair
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

R. Bradley Slease, MD
Christiana Care Health System
Newark, Delaware

Henry C. Fung, MD, FACP, FRCPE
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Manish Sharma, MD
Kimmel Cancer Center
Thomas Jefferson University
Philadelphia, Pennsylvania

Andres Ferber, MD
MD Anderson Cancer Center at Cooper
Camden, New Jersey

Lauren Berger, MPH
The Leukemia & Lymphoma Society
National Office
White Plains, New York

Ilana Benyosef, LSW
The Leukemia & Lymphoma Society
Mid-Atlantic Region
Philadelphia, Pennsylvania

TARGET AUDIENCE
This activity has been designed to meet the educational needs of hematologists-oncologists, oncologists, and other healthcare professionals involved in the care of patients with myeloma.

STATEMENT OF NEED
There has been great progress in treatment, but for most blood cancers, there is no cure and better therapies are needed. It is important for hematologists/oncologists and community oncologists to learn about new drugs in clinical trials and newly approved treatment options, as well as existing treatment options for patients with myeloma. Understanding combination therapy, dosing, and side effects management, and engaging patients in discussions about clinical trials are essential for optimal patient care. CME case study programs provide a valuable forum to learn, discuss, and share best practices for implementation in clinical practice.

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

  • Describe the latest developments in myeloma, including current and emerging treatments
  • Engage patients and caregivers in clinical trials discussions on emerging therapies for myeloma
  • Identify strategies for optimal patient care
  • Apply evidence-based treatment strategies

PHYSICIAN CONTINUING EDUCATION

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Leukemia & Lymphoma Society, RMEI, LLC, and Postgraduate Institute for Medicine. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION
Approval for nurses has been obtained by the LLS National Office under provider number CEP 5832 to award 1.75 continuing education contact hours through the California Board of Registered Nursing.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

FEE INFORMATION
There is no fee for this educational activity.

AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (physical, dietary, etc.). Please contact us prior to the live event at (866) 992-9950.

STATEMENT OF SUPPORT
This activity is jointly provided by The Leukemia & Lymphoma Society, RMEI, LLC, and Postgraduate Institute for Medicine. Funding provided by The Leukemia & Lymphoma Society.


FOLLOW LLS

Facebook Twitter YouTube


For information on leukemia, lymphoma, or myeloma contact an LLS Information Specialist at (800) 955-4572 or infocenter@LLS.org. Or visit www.LLS.org.